Driving the Development of New Therapies for Epilepsy; Accelerating the Advancement of Research from Laboratory to Person Living with Seizures

The mission of the Epilepsy Foundation - New Therapy Commercialization Grants Program is to drive the development of new therapies for epilepsy, accelerating the advancement of research from the laboratory to the patient. The Foundation funds innovative senior level research projects led by the nation's leading scientists with the potential to discover new treatment options and ultimately a cure.

Epilepsy Foundation - New Therapy Commercialization Grants Program focuses on:

  • Research with potential to discover new therapies and a cure for seizure disorders.
  • Meaningful grants to senior level scientific and clinical investigators on the brink of new discoveries, working at the nation's leading academic and research institutions, and in industry.
  • Innovative cutting edge projects that could lead to breakthrough discoveries.
  • Research programs that might not otherwise be funded through traditional sources.
  • Projects that encourage collaboration among scientists and industry.  Every day, millions of people lose seconds, minutes or hours of their lives to seizures. These precious moments can never be regained. That's why the
  • Epilepsy Foundation - New Therapy Commercialization Grants Program funds research with the potential to discover new treatment options and ultimately a cure and supports the commercialization of research originating either in the private or the academic sector in order to facilitate the development of new treatments.

Past awardees include:

  • EEG Patch | Non-Invasive Seizure Counting
    Mark Lehmkuhle, PhD
    Epitel, Inc.
    Salt Lake City, UT

    The EEG Patch is a discreet wearable EEG recording machine designed to be worn for 7 days that provides complete mobility in daily activities, including showing and sleep. The EEG Patch is noninvasive, inexpensive, discrete device designed for recording both convulsive and non-convulsive seizures.

  • Prototype of a Portable LSPR Device for PoC Measurement of AED Blood Levels
    Valentin Gribkoff, PhD
    TheraStatt LLC
    Weston, MA

    We will design a novel microfluidic diagnostic chip as a critical component of a new point of care (PoC) system for the rapid detection and monitoring of AEDs. This new PoC system will allow healthcare providers and their patients to manage AED therapy far more effectively.

  • Safety of the Hovding inflatable Helmet in Seizures
    Michael Gelfand, MD, PhD
    University of Pennsylvania
    Philadelphia, PA

    The purpose of this study is to pilot the use of a novel helmet made by Hovding Inc. which has the potential to prevent head injuries caused by seizures. Ultimately, this study will be used to power and design a larger study to determine if the device is safe and effective.

  • Focused Ultrasound for Subcortical Epilepsy (FUSE) Study
    Nathan B. Fountain MD
    University of Virginia

    Awarded $190,000

    This clinical trial will use sound waves (focused ultrasound) to selectively destroy a small area of abnormal brain cells deep in the brain, such as hypothalamic hamartomas, that cause seizures. The sound waves are focused by a new technology and directed to the correct location by live ongoing magnetic resonance imaging.

  • Dry Sensor-based Neonatal EEG Monitoring (NEMO)
    Tammy Tsuchida MD, PhD
    Children's National Medical Center

    Awarded $95,000

    The principle goal of this proposal is to design, build and test an initial Neonatal EEG Monitor ("NEMO") prototype headset that can be subsequently developed into a product ready for FDA 510(d) premarket approval as the first medical-grade neonatal dry sensor system. This easy-to-use headset will fit a range of head shapes, enable EEG recording within 10 minutes, not injure delicate neonatal skin and can be used with any conventional EEG recording system, thereby increasing availability of monitoring.

  • Disposable Chips to Measure Antiepileptic Drug Serum Concentrations at POC
    Utkan Demirci, PhD
    Stanford University
    Palo Alto, CA United States

    Awarded $150,000

    We propose to develop a disposable AED detection system to detect dose-related side-effects from seizures medication that can be performed anywhere and automated to handle a drop of blood obtained with a finger prick which can give results in approximately 10 minutes.

  • Prodrug/Enzyme Systems for Intranasal Treatment of Seizure Emergencies
    James Cloyd PharmD
    University of Minnesota, College of Pharmacy

    Awarded $40,000

    Seizure emergencies can result in injury, increased medical costs and, if left untreated, can progress to status epilepticus. The only approved out-of-hospital treatment for seizure emergencies is rectal diazepam, but many patients and caregivers object to this route. We propose to develop water-based intranasal benzodiazepines that are easily administered and safely deliver high drug concentrations that rapidly terminate seizures.

  • Factors determining placebo response in drug-resistant focal epilepsy
    Emilia Bagliella, PhD
    Icahn School of Medicine at Mount Sinai
    New York, NY, United States

    Awarded $100,000

    The magnitude of placebo response is an important factor in the outcome of clinical trials, and an inflated placebo response can obscure true drug-placebo differences.  Failure to demonstrate drug–placebo differences where true differences exist encourages sponsors to terminate drug development programs prematurely, thus preventing patient access to effective treatments.  In this project we propose to analyze a large sample of data to determine the factors that affect placebo response in clinical trials.

  • Two open-label studies of CBD in Dravet and Lennox-Gastaut syndromes
    Orrin Devinsky, MD
    New York University School of Medicine
    New York, NY, United States

    Awarded $25,000

    Listen to the Research Updates webinar on Cannabinoids in Epilepsy

    This is a joint project to investigate the safety and tolerability of a novel anti-epileptic drug, Cannabidiol (CBD). Further, the two studies outlined in this proposal will provide a first look at efficacy in seizure control in two severe childhood epilepsy syndromes – Dravet and Lennox-Gastaut.

  • MR-guided focused ultrasound for treatment of mesial TLE
    Ryder Gwinn,MD
    Swedish Neuroscience Institute
    Seattle, WA, United States

    Awarded $30,000

    This project aims to be the world's first clinical investigation of MR-guided focused ultrasound as a potential completely noninvasive and radiation-free treatment alternative for medication refractory patients with mesial temporal lobe epilepsy.

  • Minimally invasive mapping and ablation to treat epilepsy
    Gregory Worrell, MD, PhD
    Mayo Clinic
    Rochester, MN, United States

    Awarded $50,000

    Minimally invasive surgical techniques have revolutionized many areas of medicine; however, open surgery for epilepsy has remained unchanged for decades.  We propose minimally invasive catheter-based methods to replicate excellent outcomes of epilepsy surgery.  Our goals are improved outcomes, lower morbidity, lower cost and greater access to epilepsy diagnosis and treatment.

  • Counting seizures in outpatients using a wrist-worn multimodal sensor
    Daniel Friedman, MD
    New York University School of Medicine
    New York, NY United States
    Awarded $90,000

    We will exam if a new kind of sensor worn on the wrist can easily and noninvasively detect seizures. A reliable and easy to use seizure-sensor can help physicians, patients and researchers to determine the response to treatment without having to rely on the patient’s report, which may be inaccurate.

  • HE3286 treatment of drug resistant epilepsy
    Clarence Ahlem, M.S.
    Vice President
    Harbor Therapeutics, Inc.
    San Diego, CA, United States

    Awarded $62,642

    HE3286 is an anti-inflammatory drug in clinical trials for other diseases, which may provide a novel treatment for epileptic seizures that are resistant to currently approved drugs. Because brain inflammation is linked to epilepsy, we will test HE3286 in epileptic mice to see if it decreases the number or duration of chronic seizures.

Authored Date: 
Tuesday, November 5, 2013
Reviewed Date: 
Tuesday, November 5, 2013